Project Grant HT94252310908
Award Date
9/15/23
Completion Date
9/14/27
Dollars Obligated
$4.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This federal Project Grant award in the amount of $1,605,638.00 was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to The Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, a private research university and academic medical center. The grant funding supports research aimed at developing new methods for immune targeting of dormant tumor...
This federal Project Grant award for $5,238,417.00, granted by the Department of Defense's Military Medical Research and Development program (CFDA 12.420), funds a multi-year research project titled "OPTIMIZING A SURVEILLANCE STRATEGY TO TACKLE BREAST CANCER DORMANCY AND MINIMAL RESIDUAL DISEASE". The award was made on Sep 15, 2023 to The Trustees Of The University Of Pennsylvania, with an ultimate completion date of Sep 14, 2027. A key sub-award was made to Trustees Of Indiana...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
The Defense Health Agency awarded a $784,602 Project Grant to Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from January 2023 to January 2026 to develop next-generation immunotherapy for breast cancer by turning breast cancer cells against themselves. The Military Medical Research and Development program aims to transform military and public health through innovative medical...
This Defense Health Agency Project Grant award of $1,204,899 to Duke University, with a period of performance from January 1, 2024 to December 31, 2027, supports targeted vaccination research to treat and prevent endocrine-resistant ER+ breast cancer. The project aims to develop new treatments by targeting common resistance genes and neoepitope mutations. This grant is funded through the Department of Defense's Military Medical Research and Development program (CFDA 12.420), which supports...
The Trustees of the University of Pennsylvania were awarded a $1,624,578 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research into the mechanisms of mammary tumor recurrence from July 1, 2021 to June 30, 2024. Through this funding, the University of Pennsylvania will investigate medical solutions for breast cancer recurrence on the battlefield and for the American public...
The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
The Trustees of the University of Pennsylvania were awarded a $1.6 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The three-year grant will fund research on Breast Cancer Recurrence: Mechanisms and Drivers being conducted in Philadelphia, PA from July 1, 2022 through June 30, 2025. Through this funding, the University of Pennsylvania will investigate medical solutions for breast cancer recurrence and...
The federal Project Grant award of $724,500.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at Duke University to investigate "Targeting Dormancy-Associated Immune Tolerance to Eliminate Residual Breast Cancer." This award, with a performance period from March 1, 2025 to February 29, 2028, will fund advanced medical research to explore innovative approaches for treating breast cancer, with a focus on...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $1,178,136.00 to The Trustees of the University of Pennsylvania (Clinical Practices of the University of Pennsylvania) to conduct research on exploiting the absence of TP53 mutations in epithelial ovarian cancer using next-generation p53-stabilizing agents. The research project aims to develop innovative therapeutic approaches for this type of...